Neuroendocrine tumours (NETs) have a heterogeneous natural history. They often follow an indolent course, progressing slowly over many years ([@bib2]). However, the development of carcinoid heart disease is associated with adverse clinical outcomes ([@bib9]). Cardiac involvement is characterised by right-sided valvular dysfunction, which can progress to right ventricular dilatation and failure. Serotonin is implicated in the development of carcinoid heart disease ([@bib22]; [@bib11]), however high circulating levels of serotonin have a limited specificity for cardiac involvement and it is likely that there are other contributing factors to the pathogenesis of carcinoid heart disease.

Carcinoid heart disease has a significant impact on patient morbidity and mortality. Although survival from carcinoid heart disease is likely to have improved in recent years owing to the introduction and increasingly widespread use of somatostatin analogues lowering plasma serotonin concentrations, there is lack of contemporary survival data from patients diagnosed within last decade to confirm this assumption. [@bib20] demonstrated a mean survival of 1.6 years in those with cardiac involvement compared with 4.6 years in those without. Furthermore, [@bib25] found that carcinoid heart disease was the main predictor of prognosis in patients with midgut carcinoid syndrome. As moderate to severe right ventricular dilatation and New York Heart Association (NYHA) class III--IV symptoms are associated with increased mortality, it is important to screen patients to identify carcinoid heart disease as early as possible ([@bib18]).

To date, few authors have reported factors associated with the progression of carcinoid heart disease or defined which measure of progression is most useful. [@bib17], in a study of 71 patients with carcinoid syndrome and 32 patients referred directly for valve replacement, demonstrated that progression of cardiac involvement, in 35% of patients, was associated with higher urinary 5-hydroxyindoleacetic acid (5-HIAA) levels and was more likely in patients who had received chemotherapy. More recently, [@bib4] demonstrated a 17.5% progression rate in patients with carcinoid syndrome over a median follow-up duration of 29 months. Independent predictors of the development or progression of carcinoid heart disease were urinary 5-HIAA levels greater than 300 *μ*mol per24 h and three or more daily episodes of facial flushing. In both of these studies, carcinoid heart disease progression was defined as a 25% or more deterioration in the echocardiographic score of the patient. A third study, which defined progression of carcinoid heart disease as a score increase of greater than twice the s.d. of the mean intraobserver variability, also demonstrated an association between post-therapy 5-HIAA levels and the progression of carcinoid heart disease ([@bib6]). A prospective study of 80 patients with carcinoid syndrome, followed up for 26 months, demonstrated a similar progression rate of 20%, with a further 20% of patients developing carcinoid heart disease during the study period but the authors did not clearly define what was meant by 'progression\' of carcinoid heart disease, or investigate potential factors associated with progression in this cohort ([@bib15]).

It is not known how frequently NET patients should be screened for carcinoid heart disease, with consensus guidelines recommending 'regular\' echocardiography ([@bib19]). Furthermore, there is uncertainty surrounding how frequently to scan those with established carcinoid heart disease to monitor for disease progression. Identification of factors associated with the development and progression of carcinoid heart disease may aid development of more specific, evidence-based guidelines both for screening, monitoring and management of the disease.

We were unable to identify any previous studies that have assessed the progression of carcinoid heart disease in a population of patients with liver metastases, with or without the carcinoid syndrome. The purpose of this observational cohort study was therefore to prospectively identify the clinical, biochemical and radiological characteristics that are associated with the development and progression of carcinoid heart disease and overall survival in a population of patients with metastatic NETs and/or carcinoid syndrome.

Materials and methods
=====================

Recruitment
-----------

We aimed to recruit \>100 patients based on a number of factors including: (i) a conservative estimate of 20% incidence of carcinoid heart disease in our patient population; (ii) the cumulative total of patients attending each of the tertiary referral centres; and (iii) the availability of a dedicated Cardiology Research Registrar with expertise in echocardiography to recruit and study the patients.

Participants
------------

All patients with non-pancreatic NETs, liver metastases and/or carcinoid syndrome, who visited the outpatient department of one of four tertiary referral NET centres (University Hospital Aintree NHS Trust, Liverpool, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, The Christie Hospital NHS Foundation Trust, Manchester and Huddersfield Royal Infirmary, Yorkshire) between April 2009 and September 2013 were eligible to participate in this observational cohort study. The exclusion criteria included the presence of prosthetic heart valves or inadequate echocardiographic windows precluding comprehensive assessment of valve leaflet morphology, mobility and thickening. Liverpool Research Ethics Committee approved the study (reference 09/H1005/40), and all patients gave written informed consent.

Clinical assessment of disease severity
---------------------------------------

Patients\' symptoms were assessed at the time of echocardiography, with specific questions regarding frequency of flushing, diarrhoea, wheezing, breathlessness and/or ankle swelling. Carcinoid syndrome was defined as episodes of cutaneous flushing, diarrhoea or wheezing. Symptomatic progression was defined as \>50% increase in the number of daily flushing episodes or bowel movements compared with the previous visit, as used in a similar previous study ([@bib4]).

Biochemical assessment of disease severity
------------------------------------------

Venous (non-fasting) blood samples were taken on the day of baseline echocardiography and at the time of subsequent scans to determine the concentrations of N-terminal pro brain natriuretic peptide (NT-proBNP) and 5-HIAA. Plasma and serum were separated by centrifugation (3500 rpm) and stored at −80 °C until further analysis.

Biochemical assays
------------------

Our group\'s previous work has validated the use of plasma 5-HIAA and serum NT-proBNP as sensitive and specific biomarkers for the presence of carcinoid heart disease ([@bib7]). Thus, serum NT-proBNP, upper limit of normal (ULN) 146 ng l^−1^ ([@bib13]), (electrochemiluminescence technology on the fully automatic Elecsys analyser) with intra-assay precision below 4% and an inter-assay precision below 5% at concentrations above 70 pg ml^−1^ (Roche Diagnostics, Rotkreuz, Switzerland) was measured in 133 patients. Plasma 5-HIAA, ULN 118 nmol l^−1^, LC-MS/MS method (comparable to that used by [@bib24] with QuanLynx software (Waters, Watford, UK) with an inter-assay coefficient of variation of 2.6--9.8% and a intra-assay variation of 2--4.7%) ([@bib16]) was measured in 128 patients. All biochemical measurements were made without knowledge of the clinical status of the patient. Biochemical progression was defined as \>50% increase in NT-proBNP or plasma 5-HIAA from the baseline value.

Radiological assessment of disease severity
-------------------------------------------

Baseline contrast enhanced computed tomography (CT) imaging of the chest, abdomen and pelvis was performed in all patients and repeated at 12 monthly intervals. All CT scans were reviewed by radiologists with expertise in the assessment of NETs, and radiological progression was defined in accordance with the Response Evaluation Criteria in Solid Tumours (RECIST) guidelines ([@bib8]).

Echocardiographic assessment of disease progression
---------------------------------------------------

Trans-thoracic echocardiography image acquisition and analysis was performed by one of two experienced operators, using a GE Vivid 7 or Vivid Q machine (2.5 MHz phased array transducer, Horten, Norway). Valve anatomy and function were assessed in the parasternal long and short axes, and apical 4 chamber, 2 chamber and long axes. Evaluation included two-dimensional, M-mode, pulsed and continuous wave Doppler and pulsed-wave tissue Doppler imaging. Video loops were acquired triggered to the ECG (three cardiac cycles) and saved digitally for subsequent offline analysis (Echopac V9.01). Echocardiograms were performed at 12 monthly intervals, or sooner if clinically indicated.

Trans-thoracic echocardiography image analysis and interpretation
-----------------------------------------------------------------

A diagnosis of carcinoid heart disease was decided by the operator based on consensus guidelines ([@bib21]). Carcinoid heart disease was defined as thickening and reduced excursion of the four valvular leaflets, cusps and chordae, with possible consequent retraction, shortening and fixation of leaflets or cusps ([@bib21]). Valve regurgitation and stenosis was quantified according to American College of Cardiology Guidelines ([@bib5]). Tricuspid stenosis was quantified according to the mean gradient across the valve (mild 1-5 mm Hg, moderate 5--8 mm Hg, severe \>8 mm Hg). Pulmonary stenosis was quantified according to the maximum gradient across the valve (mild \<25 mm Hg, moderate 25--50 mm Hg and severe \>50 mm Hg). Regurgitation was quantified using a composite of Doppler (colour Doppler jet width and spectral density using continuous wave Doppler) and two-dimensional imaging (volume loading of the chambers). Right ventricular size and function was assessed according to the American Society of Echocardiography guidelines ([@bib23]). This enabled calculation of a previously validated echocardiographic score ([@bib3]) incorporating assessment of all four cardiac valves. Leaflet thickening, mobility and morphology, valvular regurgitation and stenosis, and right ventricular size and function were graded, with higher scores indicating more severe valvular pathology. The score ranges from 0--66, with no agreed threshold as to what defines carcinoid heart disease.

Reproducibility of echocardiographic interpretation
---------------------------------------------------

To ensure inter-observer agreement a randomly selected sub-group of 80 echocardiographic studies (58%) were cross-checked by a different observer blinded to the initial echocardiographic score. With a maximum score of 66, scores within two points were considered to be concordant. In 70 studies (88%) the assigned scores were concordant, whereas in the remaining 10 studies there was a discrepancy of \>2 points, (mean discrepency 0.234). Where there was score discordance, a third independent observer analysed the echocardiographic study, blinded to the other scores. An average of the two most concordant scores was then used for these 10 echocardiographic studies.

Categorisation of progression *vs* non-progression *vs* death
-------------------------------------------------------------

Progression of carcinoid heart disease was defined as an increase in the degree of tricuspid regurgitation, and/or an increase in the degree of tricuspid leaflet thickening or immobility. Using this definition patients were classified as progressors or non-progressors. Patients who died prior to a second echocardiogram, in whom assessment of progression was not possible, were categorised as deceased. Those who died after their second scan were classified as either progressors or non-progressors. Where a subject died prior to the second echocardiographic assessment, the interval between first assessment and date of death was recorded. We noted the presence or absence of carcinoid heart disease at baseline.

Statistical analysis
--------------------

Comparisons between continuous variables in the carcinoid heart disease and the non-carcinoid heart disease group were made using the Mann--Whitney *U*-test, as our data did not satisfy the assumption of equal variances for the two-sample *t*-test. Categorical variables were compared using the *χ*^2^- test, or Fisher\'s exact test where cell counts were insufficient. Multinomial regression was used to assess the univariate association between a number of variables and (simultaneously) disease progression and death. Statistical analyses were performed using Stata/IC 12.0 software (StataCorp LP, College Station, TX, USA). A *P*-value of \<0.05 was considered statistically significant.

Results
=======

Demographics
------------

One hundred and forty-eight patients were prospectively recruited. Four patients were lost to follow up and seven patients were excluded owing to inadequate echocardiographic windows precluding clear visualisation of all valves, resulting in a total of 137 patients studied (see [Figure 1](#fig1){ref-type="fig"}). The median duration of follow-up from first scan to last scan or death was 27 months (interquartile range 12--37), with a total of 2862 patient years. Twenty-six patients (19%) had carcinoid heart disease at the beginning of the study.

Clinical variables
------------------

During the follow-up period, nine patients had echocardiographic evidence of progression of carcinoid heart disease and four patients developed *de novo* cardiac involvement. Twenty-nine patients died in the first year of follow-up, without undergoing a second echocardiogram. The baseline characteristics of our patient population are illustrated in [Table 1](#tbl1){ref-type="table"}. There were no significant differences in age, gender or primary tumour site between the three groups. Disease duration was significantly shorter in the deceased group (15 months, *P*=0.005) but there was no difference in duration of disease between progressors and non-progressors (52 *vs* 64 months, *P*=0.554). Tumour grade differed significantly between the groups (*P*\<0.0001), with a higher proportion of grade 2 (intermediate) tumours in the progressor group, and a higher proportion of grade 3 (high grade) tumours in the deceased group. The origin of the primary tumour in those with grade 3 disease was small bowel (one patient), stomach (one patient) and recto-sigmoid (two patients). All of these patients had hepatic metastases.

Worsening of carcinoid syndrome symptoms was associated with progression of carcinoid heart disease; 85% of those with symptom deterioration demonstrated progression of carcinoid heart disease compared with 5% of those with no symptom deterioration (*P*\<0.001, [Table 2](#tbl2){ref-type="table"}). Although worsening of symptoms was independently associated with progression of carcinoid heart disease, (OR 99, 95% CI 17--573, *P*\<0.001, [Table 3](#tbl3){ref-type="table"}) the wide confidence interval implies some uncertainty in this estimate.

The numbers of patients who underwent primary tumour resection or received somatostatin receptor analogues were significantly different between the groups (see [Table 1](#tbl1){ref-type="table"}). There was, however, no difference in the proportions of patients undergoing hepatic resection, trans-arterial chemo-embolisation, targeted radionuclide therapy, radio-frequency ablation or chemotherapy between the groups. The odds of death in those who had not had a primary tumour resection was ∼3.7 times greater than in those who had undergone a primary resection (OR 3.72, 95% CI: 1.60--8.69; *P*\<0.002) but primary resection did not increase the odds of carcinoid heart disease progression (OR 2.30, 95% CI: 0.71--7.40; *P*=0.164).

Biochemical variables
---------------------

Baseline plasma 5-HIAA and NT-proBNP concentrations were significantly different between the groups ([Table 1](#tbl1){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}), with the highest NT-proBNP levels seen in the deceased group and the highest 5-HIAA concentrations in the progressors. Baseline 5-HIAA concentration was significantly associated with disease progression: every 100 nmol l^−1^ increase in 5-HIAA yielded a 5% greater odds of disease progression (OR 1.05, 95% CI: 1.01, 1.09; *P*=0.012) and 7% higher odds of death before second follow-up (OR 1.07, 95% CI: 1.03, 1.10; *P*=0.001, see [Table 3](#tbl3){ref-type="table"}). The proportion of patients with NT-proBNP or 5-HIAA progression was significantly higher in the progressors compared with the non-progressors (62% *vs* 31%, *P*=0.04 and 46% *vs* 18%, *P*=0.035, respectively, see [Table 2](#tbl2){ref-type="table"}).

Radiological variables
----------------------

Increase in tumour bulk was not associated with progression of carcinoid heart disease; 10% of those with stable disease demonstrated progression of carcinoid heart disease compared with 13% of those with an increase in tumour bulk (*P*=0.669), OR 0.76 (95% CI 0.22--2.66, *P*=0.670, [Table 3](#tbl3){ref-type="table"}).

Carcinoid heart disease score
-----------------------------

Increasing echocardiographic score was an independent predictor of both carcinoid heart disease progression and death. A five-point increase in the score was associated with an odds ratio of 2.95 (95% CI 1.71--5.09, *P*\<0.005) for carcinoid heart disease progression and 2.66 (95% CI 1.63--4.35, *P*\<0.005) for death.

Death
-----

The deceased patients had significantly shorter durations of disease (15 months *vs* 64 months in the non-progressors and 52 months in the progressors, *P*=0.005). They also had histologically more aggressive tumours (14% high-grade *vs* 0% in the other groups, *P*\<0.001). Of the 29 deceased patients, 12 (41%) had carcinoid heart disease. In a univariate Cox proportional hazard model, the risk of death in those with carcinoid heart disease at baseline was significantly greater than in those without carcinoid heart disease (hazard ratio 3.61, 95% CI (1.69--7.69), *P*=0.001). [Figure 3](#fig3){ref-type="fig"} shows Kaplan--Meier survival estimates according to presence or absence of baseline carcinoid heart disease.

Discussion
==========

In this large, prospective, observational cohort study we have demonstrated that biochemical variables, in particular baseline plasma 5-HIAA concentration, are independently associated with carcinoid heart disease progression in patients with metastatic NETs and have greater prognostic value than clinical or radiological variables.

Our finding of the value of plasma 5-HIAA concentration in the prediction of carcinoid heart disease progression is consistent with results from [@bib4] and [@bib17] who demonstrated similar associations between carcinoid heart disease progression and urinary 5-HIAA concentrations. Serotonin is a major biochemical mediator of carcinoid heart disease ([@bib12]; [@bib14]) and therefore the measurement of its main metabolite, 5-HIAA, is a logical biomarker to measure. Plasma measurement of 5-HIAA is easier for the patient, and correlates well with the more traditional 24 h urinary measurement ([@bib24]). We have also demonstrated that both NT-proBNP and 5-HIAA are independently associated with death in patients with metastatic NETS and/or carcinoid syndrome. An elevated NT-proBNP concentration may reflect other factors known to increase risk of death such as NYHA class III--IV or right ventricular dilatation. Biochemical measurement is, however, a more objective measurement than attempting to evaluate NYHA class, which is notoriously difficult to estimate ([@bib10]).

Patients with symptomatic deterioration were more likely to demonstrate carcinoid heart disease progression than those with stable symptoms. This finding is similar to that of [@bib4] and is likely to be due to higher serotonin levels in the patients, with worsening symptoms of the carcinoid syndrome. Use of somatostatin analogue therapy was more common in the progressors, which may be a reflection of more advanced disease in this patient group.

We found no relationship between radiological progression and progression of carcinoid heart disease. However, resection of the primary tumour was more common in the non-progressors than in the progressors or deceased groups. This may support previous findings suggesting that a reduction in tumour burden by hepatic resection may decrease the risk of progression of carcinoid heart disease through the reduction in circulating hormone levels ([@bib1]).

The rate of progression of carcinoid heart disease is difficult to estimate owing to the number of deaths in our study (no progression data available for these patients). The progression rate could be as low as 10% (13/137) or as high as 31% (42/137), but is likely to fall somewhere within this range, in keeping with the progression rates of similar studies ([@bib17]; [@bib4]).

There are several limitations to our study to acknowledge. First is the lack of a standardised definition of carcinoid heart disease progression, although this can be applied to all similar studies. As the echocardiographic score assesses both sides of the heart, an increase in the score could be due to coexisting pathology such as degenerative mitral valve disease, and therefore using an absolute increase in the echocardiographic score as the determinant of carcinoid heart disease progression would lead to an overestimate of the number of patients demonstrating progression. For this reason we used a clinical definition. We also acknowledge the relatively short duration of follow-up in our study and the heterogeneity of the study population with differences in tumour biology/grade, types and duration of treatment modalities and duration of diagnosis. This limitation may be overcome in larger, perhaps national studies, in which common therapeutic pathways and algorithms may be adopted and longer-term outcome available. Finally, the cause of death was unknown and it is uncertain in all individuals whether death was attributable to NET disease progression, to carcinoid heart disease progression or to an unrelated cause.

The findings of this study suggest that it is the biochemical or hormonal burden of disease, rather than radiological extent or duration of disease that dictates development and progression of carcinoid heart disease. This implies that any treatments, medical (e.g. somatostatin analogues) or surgical (resection of primary tumour) that reduce secretion of vasoactive substances may be protective against the development and progression of carcinoid heart disease.
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###### Baseline characteristics of patients

  **Variable**                                              **Progression of carcinoid heart disease (*****n*****=13)**   **No progression of carcinoid heart disease (*****n*****=95)**   **Died prior to 2nd echo (*****n*****=29)**   ***P*****-value**
  --------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------- --------------------------------------------- -------------------
  **Demographics**                                                                                                                                                                                                                       
  Age (years)[a](#t1-fn1){ref-type="fn"}                    68±13                                                         67±10                                                            70±11                                         0.112
  Male sex (no %)                                           5 (39%)                                                       55 (58%)                                                         16 (55%)                                      0.417
  Follow-up (months)[b](#t1-fn2){ref-type="fn"}             29 (13--41)                                                   27 (12--37)                                                      ---                                           0.887
  **Clinical characteristics**                                                                                                                                                                                                           
  **Tumour grade (no %)**                                                                                                                                                                                                                
   Grade 1                                                  1 (8%)                                                        55 (58%)                                                         9 (31%)                                       **0.007**
   Grade 2                                                  3 (23%)                                                       7 (7%)                                                           2 (7%)                                         
   Grade 3                                                  0                                                             0                                                                4 (14%)                                        
   Unknown                                                  9 (69%)                                                       33 (35%)                                                         14 (48%)                                       
  Duration of disease (months)[b](#t1-fn2){ref-type="fn"}   52 (27--138)                                                  64 (40--88)                                                      15 (9--59)                                    **0.005**
  **Site of primary tumour**                                                                                                                                                                                                             
   Small bowel                                              8 (62%)                                                       71 (75%)                                                         19 (66%)                                      0.126
   Large bowel                                              1 (8%)                                                        7 (7%)                                                           1 (3%)                                         
   Lung                                                     0                                                             1 (1%)                                                           2 (7%)                                         
   Other                                                    1 (8%)                                                        1 (1%)                                                           3 (10%)                                        
   Unknown                                                  3 (24%)                                                       15 (16%)                                                         4 (14%)                                        
  Liver metastases                                          11 (85%)                                                      80 (84%)                                                         27 (93%)                                      0.473
  Carcinoid syndrome                                        12 (92%)                                                      63 (66%)                                                         21 (72%)                                      0.151
  Baseline carcinoid heart disease                          9 (70%)                                                       5 (5%)                                                           12 (41%)                                      **\<0.001**
  Baseline echocardiographic score                          9 (7.5--14)                                                   3 (1--5)                                                         5 (2.5--14.5)                                 **\<0.001**
  Baseline NT-proBNP (ng l^−1^)                             267 (108--578)                                                84 (29--224)                                                     401 (116--978)                                **0.001**
  Baseline 5-HIAA (nmol l^−1^)                              2247 (807--2939)                                              316 (138--661)                                                   1221 (167--437)                               **0.009**
  **Therapeutic intervention**                                                                                                                                                                                                           
  SSA therapy                                               12 (92%)                                                      78 (82%)                                                         17 (59%)                                      **0.012**
  Primary tumour resection                                  6 (46%)                                                       63 (66%)                                                         7 (24%)                                       **\<0.001**
  Resection of hepatic metastases                           1 (8%)                                                        9 (10%)                                                          2 (7%)                                        0.903
  Interferon                                                0                                                             8 (8%)                                                           2 (7%)                                        0.547
  Chemotherapy                                              0                                                             10 (10%)                                                         6 (21%)                                       0.111
  Targeted radionuclide therapy                             4 (31%)                                                       27 (28%)                                                         4 (14%)                                       0.259
  Chemo-embolisation                                        1 (8%)                                                        11 (12%)                                                         0                                             0.154
  Radio-frequency ablation                                  0                                                             6 (6%)                                                           0                                             0.25

Mean±s.d.

Median and interquartile range, SSA somatostatin analogue. Significant *P*-values (\<0.05) are indicated in bold.

###### Association of variables with progression of carcinoid heart disease

  **Variable**                                           **Progression of carcinoid heart disease (*****n*****=13)**   **No progression of carcinoid heart disease (*****n*****=95)**   ***P*****-value**
  ------------------------------------------------------ ------------------------------------------------------------- ---------------------------------------------------------------- -------------------
  Symptomatic deterioration[a](#t2-fn1){ref-type="fn"}   11 (85%)                                                      5 (5%)                                                           **\<0.001**
  NT-proBNP progression[b](#t2-fn2){ref-type="fn"}       8 (62%)                                                       24 (31%)                                                         **0.04**
  Plasma 5-HIAA progression[b](#t2-fn2){ref-type="fn"}   6 (46%)                                                       14 (18%)                                                         **0.035**
  Radiological progression[c](#t2-fn3){ref-type="fn"}    4 (31%)                                                       35 (37%)                                                         0.461

\>50% increase in the number of daily flushing episodes or bowel movements compared with the previous visit.

\>50% increase from the baseline value.

in accordance with RECIST (Response Evaluation Criteria in Solid Tumors) guidelines. Significant *P*-values (\<0.05) are indicated in bold.

###### Multinomial logistic regression analysis

  **Variable**                           **Unit change**         **Group**                      **OR (95% CI)**              ***P*****-value**
  -------------------------------------- ----------------------- ------------------- ------------------------------------- ---------------------
  Age (years)                            5 years 5 years         Progression Death    1.09 (0.82--1.45) 1.16 (0.94--1.43)       0.570 0.167
  Disease duration (months)              100 months 100 months   Progression Death    0.99 (0.36--2.72) 0.22 (0.07--0.73)     0.986 **0.013**
  Symptom deterioration                  ---                     Progression                     99 (17--573)                   **\<0.001**
  Baseline NT-proBNP (ng l^−1^)          100 units 100 units     Progression Death    1.04 (0.92--1.18) 1.11 (1.02--1.21)     0.486 **0.014**
  Baseline 5-HIAA (nmol l^−1^)           100 units 100 units     Progression Death    1.05 (1.01--1.09) 1.07 (1.03--1.10)   **0.012** **0.001**
  Radiological increase in tumour bulk   ---                     Progression                   0.76 (0.22--2.66)                   0.670

Significant *P*-values (\<0.05) are indicated in bold.
